Altimmune Reports Q1 2026 Results, $535M Cash, and Advances Pemvidutide Clinical Trials
ALT sits 21% above its 52-week low of $2.56.
Summary
Altimmune announced its Q1 2026 financial results, reporting a strong cash position of $535 million and providing positive updates on its pemvidutide clinical development, including a planned Phase 3 MASH trial.
Key Events · Earnings and Guidance · ALT
-
Strong Cash Position Reported
The company reported $332 million in cash, cash equivalents, and short-term investments as of March 31, 2026, further increasing to $535 million by April 30, 2026, following recent public offerings.
-
Pemvidutide Phase 3 MASH Trial Planned
Altimmune plans to initiate its global PERFORMA Phase 3 MASH trial for pemvidutide in the second half of 2026, with 52-week data anticipated in 2029. The study protocol has been finalized and submitted to the FDA.
-
Upcoming Clinical Data Readouts
Topline data from the RECLAIM Phase 2 AUD trial is expected in Q3 2026, and enrollment completion for the RESTORE Phase 2 ALD trial is also anticipated in Q3 2026.
-
Q1 2026 Financial Performance
The company reported a net loss of $22.6 million, or $0.18 per share, for the first quarter of 2026, compared to a net loss of $19.6 million, or $0.26 per share, in the same period of 2025.
Analysis · ALT · Life Sciences
Altimmune reported its first quarter 2026 financial results, highlighting a significantly strengthened balance sheet with $535 million in cash as of April 30, 2026. This substantial cash position, largely due to recent public offerings, provides a long runway for the company's clinical programs. The company also provided positive updates on its lead drug pemvidutide, including plans to initiate a Phase 3 MASH trial in the second half of 2026 and upcoming data readouts for its AUD and ALD trials, reinforcing its development pipeline.
At the time of this filing, ALT was trading at $3.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $598.6M. The 52-week trading range was $2.56 to $7.73. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.